Ratings Medigene AG OTC Markets

Equities

MDGEF

DE000A1X3W00

Market Closed - OTC Markets Other stock markets 08:06:56 28/03/2024 pm IST			5-day change	1st Jan Change
2.297 ^USD	-11.96%		-5.49%	+53.10%

03/07	Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	CI
27/06	Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEDIGENE AG	+53.10%	3.79Cr	-
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr	B+
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr	B+
ARGENX SE	+25.44%	2.79TCr	B
BIONTECH SE	-17.74%	2.1TCr	B+
GENMAB A/S	-15.17%	1.69TCr	A-
BEIGENE, LTD.	-15.21%	1.62TCr	B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr	C+
WUXI APPTEC CO., LTD.	-47.10%	1.48TCr	A-
SAREPTA THERAPEUTICS, INC.	+54.50%	1.41TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes